Testing two medications together for advanced pancreatic neuroendocrine tumors

This is a Phase I trial testing whether fulvestrant, combined with Lu-DOTATATE (a radioactive treatment), can safely treat pancreatic neuroendocrine tumors that have spread to other parts of the body or cannot be surgically removed. The researchers want to see if combining these two medications together works better than using them separately, and whether the combination is safe and tolerable for patients. The trial is recruiting 25 patients and will start by carefully monitoring the first 6 participants for safety before expanding to enroll more.

Patients with advanced pancreatic neuroendocrine tumors have limited treatment options and shortened lifespans. While Lu-DOTATATE (a radioactive peptide therapy) has improved outcomes, it often only slows disease rather than stopping it. Early laboratory research suggests that combining this medication with fulvestrant—a medication that blocks a hormone receptor—might make the treatment more effective, but this combination has never been tested in patients before.